Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
News about Predictmedix AI Inc. (PMEDF) centers on its development of AI-powered health and safety technology, rapid health screening, and remote patient care platforms. Company announcements describe SmartHealth AI stations and Safe Entry Stations that use proprietary artificial intelligence and multispectral cameras to analyze physiological data patterns, predict vital parameters, and assess issues such as impairment, fatigue, and certain mental illnesses.
Recent releases highlight a multi-vertical growth strategy built around a single Core AI Engine. News items cover the launch of a Clinical-Trial AI Platform designed to simulate and optimize clinical trials, including features like adaptive simulations, patient-site optimization, cost and ROI modeling, and compliance-integrated AI. Other updates describe expansion into consumer digital health through a mobile diabetes screening platform that uses AI-driven facial and biometric analysis via smartphone for non-invasive diabetic risk scoring.
Investors and observers can also find coverage of Predictmedix AI’s capital markets activity, including non-brokered private placements, insider participation, and the stated use of proceeds to advance its AI engine, SmartHealth AI Station certification initiatives, clinical-trial applications, and B2C mobile platforms. Additional news includes participation in international investor conferences and roadshows, as well as selection for a Canadian government trade mission to Mexico to explore commercial opportunities for its health and safety technologies.
Together, these news items provide insight into how Predictmedix AI positions itself at the intersection of AI, quantum-inspired computation, and healthcare, and how it is communicating its technology roadmap, financing plans, and international engagement to the market.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) has initiated the deployment of its COVID-19 symptom mass screening technology at Flow Water and a 24-hour pharmacy in Montreal. This partnership, outlined on August 17, 2020, aims to enhance health measures in essential businesses to mitigate COVID-19 risks.
The technology, implemented in collaboration with JUICEWORKS EXHIBITS, is designed to provide an extra layer of safety for employees and customers. The pharmacy's deployment is expected within 2-3 weeks, addressing health safety in a critical retail environment.
Predictmedix Inc. (CSE:PMED, OTCQB:PMEDF) announces the deployment of its COVID-19 and impairment screening technology at Indian Oil Corporation Ltd, a Fortune 500 company. The deployment will begin in 3-4 weeks, marking Predictmedix's entry into the Oil & Gas sector. Additionally, the company appointed Kiran Kumari to its advisory board for business development in the Asia Pacific region. Predictmedix also filed a US patent application for a healthcare provider reward management system, further enhancing its telehealth capabilities. The company aims to address health safety across workplaces.